Stockscreener 앱 받기
0.1482
3.39%
-0.0052
전일 마감가:
$0.1534
열려 있는:
$0.142
하루 거래량:
49.21M
Relative Volume:
22.65
시가총액:
$13.45M
수익:
-
순이익/손실:
$-31.88M
주가수익비율:
-0.1976
EPS:
-0.75
순현금흐름:
$-25.20M
1주 성능:
+2.28%
1개월 성능:
-13.84%
6개월 성능:
-51.36%
1년 성능:
-85.61%
1일 변동 폭
$0.1285
$0.1521
1주일 범위
$0.1285
$0.187
52주 변동 폭
$0.112
$1.74
인에잇바이오 Stock (INAB) Company Profile
명칭
In 8 Bio Inc
전화
(646) 600-6438
주소
EMPIRE STATE BUILDING, NEW YORK
INAB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INAB
In 8 Bio Inc
|
0.1482 | 13.15M | 0 | -31.88M | -25.20M | -0.75 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
인에잇바이오 Stock (INAB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-03-18 | 개시 | Laidlaw | Buy |
| 2022-08-30 | 개시 | H.C. Wainwright | Buy |
인에잇바이오 주식(INAB)의 최신 뉴스
Fierce Biotech Layoff Tracker 2025: Keros cuts 70 jobs; iTeos winds down - Fierce Biotech
Analysts Set Cabaletta Bio, Inc. (NASDAQ:CABA) Price Target at $20.33 - MarketBeat
Palisade Bio Reports Positive Phase 1a Results for - GlobeNewswire
Global Immunoprecipitation Market Set to Grow at a CAGR of 6-8%: Key Drivers and Challenges by 2029 - PharmiWeb.com
DNA Polymerase Market to Grow at 6–8% CAGR Driven by Genomics, PCR, and CRISPR Technologies by 2029 - PharmiWeb.com
Layoff Tracker: Boundless Laying Off 33% of Staff - BioSpace
Caisse Française de Financement Local: EMTN 2025-8 SOCIAL - The Manila Times
Dimensional Fund Advisors LP Sells 592,968 Shares of bluebird bio, Inc. (NASDAQ:BLUE) - Defense World
KALA BIO: Q1 Earnings Snapshot - The Washington Post
KALA BIO Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Raymond James Financial Inc. Takes Position in 8×8, Inc. (NASDAQ:EGHT) - Defense World
Why INmune Bio Inc (INMB) Is Skyrocketing So Far In 2025 - MSN
INmune Bio, Inc. (NASDAQ:INMB) Q1 2025 Earnings Call Transcript - Insider Monkey
Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation - GlobeNewswire
TELA Bio, Inc. (NASDAQ:TELA) Q1 2025 Earnings Call Transcript - Insider Monkey
8 Best Medical Simulators On Steam, Ranked - Game Rant
Nuvation Bio Inc. (NUVB): Among Billionaire David Abrams’ Stock Picks with Huge Upside Potential - Yahoo Finance
bluebird bio, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before May 28, 2024 to Discuss Your RightsBLUE - ACCESS Newswire
Shareholders that lost money on bluebird bio, Inc. (BLUE) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
INmune Bio Inc. Announces First Quarter 2025 Results and Provides Business Update - Yahoo Finance
TELA Bio Reports First Quarter 2025 Financial Results - Yahoo Finance
GRI Bio’s Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”) - Yahoo Finance
IN8bio Reports First Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewswire Inc.
TELA Bio Inc (TELA) Q1 2025 Earnings Report Preview: What to Expect - Yahoo Finance
GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”) - Yahoo Finance
TELA Bio Inc expected to post a loss of 20 cents a shareEarnings Preview - TradingView
Instil Bio Inc expected to post a loss of $2.59 a shareEarnings Preview - TradingView
Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases - GlobeNewswire
INmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on Thursday, May 8th - The Manila Times
Press Release Distribution & PR Platform - ACCESS Newswire
Nuvation Bio CFO to Share Latest Oncology Strategy at Exclusive Citizens Conference Next Week - Stock Titan
Palisade Bio’s AI-Driven Approach to IBD Heterogeneity and - GlobeNewswire
Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference - BioSpace
Annovis Bio Appoints Hui Liu as Director of Biostatistics - GlobeNewswire
Belite Bio Announces Poster Presentations at the Association for Research in Vision and Ophthalmology 2025 Annual Meeting - Yahoo Finance
Cerity Partners LLC Makes New Investment in Nuvation Bio Inc. (NYSE:NUVB) - Defense World
Tevogen Bio Announces 2025 Annual Meeting - GlobeNewswire
TELA Bio to Announce Q1 2025 Earnings on May 8 - MSN
TELA Bio to Announce First Quarter 2025 Financial Results - The Manila Times
Tevogen Bio Signs Agreement with CD 8 Technology - TipRanks
Medical Tech Leader TELA Bio Schedules Q1 2025 Earnings: Key Growth Updates Expected - Stock Titan
Is Gossamer Bio Inc. (NASDAQ:GOSS) the Best Penny Stock to Invest in Under $1? - Insider Monkey
GRI Bio Announces Abstract Selected for Poster Discussion Session at the 2025 American Thoracic Society (ATS) International Conference - Yahoo Finance
Vyant Bio (OTCMKTS:VYNT) Trading 7.8% Higher – Time to Buy? - Defense World
Amtech Systems, Tesla And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108 - GlobeNewswire
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)April 8, 2025 - BioSpace
South Korean firms ABL Bio, Yuhan advance bispecific antibodies in cancer treatment - Chosunbiz
인에잇바이오 (INAB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.89%
3.74%
자본화:
|
볼륨(24시간):